

Applicant: .Donovan
Serial No.: 09/810,601
Filed: March 15, 2001
Page 2 of 2

The Office Action states that the Sequence Listing submitted December 23, 2002 did not comply with all of the requirements of 37 CFR 1.822 and/or 1.823. A paper copy and a computer readable form of a corrected Sequence Listing are enclosed herewith. Applicant submits that all of the requirements of 37 CFR 1.822 and/or 1.823 have been met. The enclosed Sequence Listing is to be substituted for any previously filed Sequence Listing currently in the file.

In addition, a copy of the Notice to Comply, and a Declaration Pursuant to 37 C.F.R. § 1.821(f) are also enclosed.

In conclusion, applicant submits that the application is in proper form, and requests a favorable action on the merits.

Date: February 21, 2003


Respectfully submitted,



Frank J. Uxa

Attorney for Applicant
Registration No. 25,612
4 Venture, Suite 300
Irvine, California 92618
(949) 450-1750
(949) 450-1764 Facsimile

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202, on : February 21, 2003


Assistant



Feb-06-03 10:03pm

From-ALLERGAN LEGAL DEPARTMENT

+17142464248

T-237 P.06/14 F-818

Application No.: **09/810,601****NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set by the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: See Raw Sequence Listing Error Report

RECEIVED

MAR 06 2003

Applicant Must Provide:


- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g).

TECH CENTER 1600/2900

For questions regarding compliance to these requirements, please contact:


- For Rules Interpretation, call (703) 308-4216 or (703) 308-2923
- For CRF Submission Help, call (703) 308-4212
- For PatentIn software Program Support:
 - HELP DESK: (703) 739-8559, ext 508, M-F, 8 AM to 5 PM EST except holidays
 - Email: PATIN21HELP@uspto.gov
 - To purchase PatentIn software: (703) 306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE



RAW SEQUENCE LISTING ERROR REPORT

BIOTECHNOLOGY
SYSTEMS
BRANCH



RECEIVED

FEB 28 2003

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/810,601A

Source: 1600 PUSH

Date Processed by STIC: 1/15/2003

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin2help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>


Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/efb/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name,
Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two,
2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office,
Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002



1600

RAW SEQUENCE LISTING

DATE: 01/15/2003

PATENT APPLICATION: US/09/810,601A

TIME: 18:15:08

Input Set : A:\D2947CIP 021211.ST25.txt

Output Set: N:\CRF4\01152003\I810601A.raw

3 <110> APPLICANT: Allergan Sales, Inc.
4 Donovan, Stephen
6 <120> TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING GONADOTROPHIN RELATED
ILLNESSES
8 <130> FILE REFERENCE: D-2947-CIP
10 <140> CURRENT APPLICATION NUMBER: 09/810,601A
11 <141> CURRENT FILING DATE: 2001-03-15
13 <150> PRIOR APPLICATION NUMBER: 09/692,811
14 <151> PRIOR FILING DATE: 2000-10-20
16 <160> NUMBER OF SEQ ID NOS: 52
18 <170> SOFTWARE: PatentIn version 3.1
20 <210> SEQ ID NO: 1
21 <211> LENGTH: 10
22 <212> TYPE: PRT
23 <213> ORGANISM: Homo sapiens
25 <220> FEATURE:
26 <221> NAME/KEY: MISC_FEATURE
27 <222> LOCATION: (1)..(1)
28 <223> OTHER INFORMATION: Xaa at position 1 is PyroGlu
31 <400> SEQUENCE: 1
W--> 33 Xaa His Trp Ser Tyr Gly Leu Arg Pro Gly
34 1 5 10
37 <210> SEQ ID NO: 2
38 <211> LENGTH: 10
39 <212> TYPE: PRT
40 <213> ORGANISM: Artificial Sequence
42 <220> FEATURE:
43 <223> OTHER INFORMATION: Gonadotrophin Release Hormone Analogue
45 <220> FEATURE:
46 <221> NAME/KEY: MISC_FEATURE
47 <222> LOCATION: (1)..(1)
48 <223> OTHER INFORMATION: Xaa at position 1 is PyroGlu
51 <220> FEATURE:
52 <221> NAME/KEY: MISC_FEATURE
53 <222> LOCATION: (10)..(10)
54 <223> OTHER INFORMATION: Xaa at position 1 is Gly-NH2
57 <400> SEQUENCE: 2
W--> 59 Xaa His Trp Ser Tyr Gly Leu Arg Pro Xaa
60 1 5 10
63 <210> SEQ ID NO: 3
64 <211> LENGTH: 10
65 <212> TYPE: PRT
66 <213> ORGANISM: Artificial Sequence
68 <220> FEATURE:

Does Not Comply
Corrected Diskette Needed

pp 1-6



RAW SEQUENCE LISTING

DATE: 01/15/2003

PATENT APPLICATION: US/09/810,601A


TIME: 18:15:08

Input Set : A:\D2947CIP 021211.ST25.txt

Output Set: N:\CRF4\01152003\I810601A.raw

69 <223> OTHER INFORMATION: Gonadotrophin Release Hormone Analogue
71 <220> FEATURE:
72 <221> NAME/KEY: MISC_FEATURE
73 <222> LOCATION: (1)..(1)
74 <223> OTHER INFORMATION: Xaa at position 1 is PyroGlu
77 <220> FEATURE:
78 <221> NAME/KEY: MISC_FEATURE
79 <222> LOCATION: (10)..(10)
80 <223> OTHER INFORMATION: Xaa at position 10 is ethylamide
83 <400> SEQUENCE: 3
W--> 85 Xaa His Trp Ser Tyr Gly Leu Arg Pro Xaa
86 1 5 10
89 <210> SEQ ID NO: 4
90 <211> LENGTH: 10
91 <212> TYPE: PRT
92 <213> ORGANISM: Artificial Sequence
94 <220> FEATURE:
95 <223> OTHER INFORMATION: Gonadotrophin Release Hormone Analogue
97 <220> FEATURE:
98 <221> NAME/KEY: MISC_FEATURE
99 <222> LOCATION: (1)..(1)
100 <223> OTHER INFORMATION: Xaa at position 1 is PyroGlu
103 <220> FEATURE:
104 <221> NAME/KEY: MISC_FEATURE
105 <222> LOCATION: (10)..(10)
106 <223> OTHER INFORMATION: Xaa at position 10 is Aza-Gly-NH2
109 <400> SEQUENCE: 4
OK 111 Xaa His Trp Ser Tyr Gly Leu Arg Pro Xaa
112 1 5 10
115 <210> SEQ ID NO: 5
116 <211> LENGTH: 10
117 <212> TYPE: PRT
118 <213> ORGANISM: Artificial Sequence
120 <220> FEATURE:
121 <223> OTHER INFORMATION: Gonadotrophin Release Hormone Analogue
123 <220> FEATURE:
124 <221> NAME/KEY: MISC_FEATURE
125 <222> LOCATION: (1)..(1)
126 <223> OTHER INFORMATION: Xaa at position 1 is PyroGlu
129 <220> FEATURE:
130 <221> NAME/KEY: MISC_FEATURE
131 <222> LOCATION: (10)..(10)
132 <223> OTHER INFORMATION: Xaa at position 10 is Gly-NH2
135 <400> SEQUENCE: 5
OK 137 Xaa His Trp Ser Tyr Lys Leu Arg Pro Xaa
138 1 5 10
141 <210> SEQ ID NO: 6
142 <211> LENGTH: 10
143 <212> TYPE: PRT

- How is this?
Xaa can only
represent
a single
amino acid,
nothing else



FEB 27 2003 04:04pm

From-ALLERGAN LEGAL DEPARTMENT

+17142464249

T-237 P.10/14 F-818

RAW SEQUENCE LISTING

DATE: 01/15/2003

PATENT APPLICATION: US/09/810,601A

TIME: 18:15:08

Input Set : A:\D2947CIP 021211.ST25.txt

Output Set: N:\CRF4\01152003\I810601A.raw

144 <213> ORGANISM: Artificial Sequence
146 <220> FEATURE:
147 <223> OTHER INFORMATION: Gonadotrophin Release Hormone Analogue
149 <220> FEATURE:
150 <221> NAME/KEY: MISC_FEATURE
151 <222> LOCATION: (1)..(1)
152 <223> OTHER INFORMATION: Xaa at position 1 is PyroGlu
155 <220> FEATURE:
156 <221> NAME/KEY: MISC_FEATURE
157 <222> LOCATION: (10)..(10)
158 <223> OTHER INFORMATION: Xaa at position 10 is ethylamide
161 <400> SEQUENCE: 6
W--> 163 Xaa His Trp Ser Tyr Lys Leu Arg Pro Xaa
164 1 5 10
167 <210> SEQ ID NO: 7
168 <211> LENGTH: 10
169 <212> TYPE: PRT
170 <213> ORGANISM: Artificial Sequence
172 <220> FEATURE:
173 <223> OTHER INFORMATION: Gonadotrophin Release Hormone Analogue
175 <220> FEATURE:
176 <221> NAME/KEY: MISC_FEATURE
177 <222> LOCATION: (1)..(1)
178 <223> OTHER INFORMATION: Xaa at position 1 is PyroGlu
181 <220> FEATURE:
182 <221> NAME/KEY: MISC_FEATURE
183 <222> LOCATION: (10)..(10)
184 <223> OTHER INFORMATION: Xaa at position 10 is Aza-Gly-NH2
187 <400> SEQUENCE: 7
OK-> 189 Xaa His Trp Ser Tyr Lys Leu Arg Pro Xaa
190 1 5 10
193 <210> SEQ ID NO: 8
194 <211> LENGTH: 10
195 <212> TYPE: PRT
196 <213> ORGANISM: Artificial Sequence
198 <220> FEATURE:
199 <223> OTHER INFORMATION: Gonadotrophin Release Hormone Analogue
201 <220> FEATURE:
202 <221> NAME/KEY: MISC_FEATURE
203 <222> LOCATION: (1)..(1)
204 <223> OTHER INFORMATION: Xaa at position 1 is PyroGlu
207 <220> FEATURE:
208 <221> NAME/KEY: MISC_FEATURE
209 <222> LOCATION: (6)..(6)
210 <223> OTHER INFORMATION: Xaa at position 6 is D-Lys
213 <220> FEATURE:
214 <221> NAME/KEY: MISC_FEATURE
215 <222> LOCATION: (10)..(10)
216 <223> OTHER INFORMATION: Xaa at position 10 is Gly-NH2

RAW SEQUENCE LISTING

DATE: 01/15/2003

PATENT APPLICATION: US/09/810,601A

TIME: 18:15:08

Input Set : A:\D2947CIP 021211.ST25.txt

Output Set: N:\CRF4\01152003\I810601A.raw

OK 219 <400> SEQUENCE: 8
221 Xaa His Trp Ser Tyr Xaa Leu Arg Pro Xaa
222 1 5 10
225 <210> SEQ ID NO: 9
226 <211> LENGTH: 10
227 <212> TYPE: PRT
228 <213> ORGANISM: Artificial Sequence
230 <220> FEATURE:
231 <223> OTHER INFORMATION: Gonadotrophin Release Hormone Analogue
233 <220> FEATURE:
234 <221> NAME/KEY: MISC_FEATURE
235 <222> LOCATION: (1)..(1)
236 <223> OTHER INFORMATION: Xaa at position 1 is PyroGlu
239 <220> FEATURE:
240 <221> NAME/KEY: MISC_FEATURE
241 <222> LOCATION: (6)..(6)
242 <223> OTHER INFORMATION: Xaa at position 6 is D-Lys
245 <220> FEATURE:
246 <221> NAME/KEY: MISC_FEATURE
247 <222> LOCATION: (10)..(10)
248 <223> OTHER INFORMATION: Xaa at position 10 is ethylamide ✓
251 <400> SEQUENCE: 9
W--> 253 Xaa His Trp Ser Tyr Xaa Leu Arg Pro Xaa
254 1 5 10
257 <210> SEQ ID NO: 10
258 <211> LENGTH: 10
259 <212> TYPE: PRT
260 <213> ORGANISM: Artificial Sequence
262 <220> FEATURE:
263 <223> OTHER INFORMATION: Gonadotrophin Release Hormone Analogue
265 <220> FEATURE:
266 <221> NAME/KEY: MISC_FEATURE
267 <222> LOCATION: (1)..(1)
268 <223> OTHER INFORMATION: Xaa at position 1 is PyroGlu
271 <220> FEATURE:
272 <221> NAME/KEY: MISC_FEATURE
273 <222> LOCATION: (6)..(6)
274 <223> OTHER INFORMATION: Xaa at position 6 is D-Lys
277 <220> FEATURE:
278 <221> NAME/KEY: MISC_FEATURE
279 <222> LOCATION: (10)..(10)
280 <223> OTHER INFORMATION: Xaa at position 10 is Aza-Gly-NH2
283 <400> SEQUENCE: 10
OK--> 285 Xaa His Trp Ser Tyr Xaa Leu Arg Pro Xaa
286 1 5 10
289 <210> SEQ ID NO: 11
290 <211> LENGTH: 10
291 <212> TYPE: PRT
292 <213> ORGANISM: Artificial Sequence

RAW SEQUENCE LISTING

DATE: 01/15/2003

PATENT APPLICATION: US/09/810,601A

TIME: 18:15:08

Input Set : A:\D2947CIP 021211.ST25.txt

Output Set: N:\CRF4\01152003\I810601A.raw

294 <220> FEATURE:
295 <223> OTHER INFORMATION: Gonadotrophin Release Hormone Analogue
297 <220> FEATURE:
298 <221> NAME/KEY: MISC_FEATURE
299 <222> LOCATION: (1)..(1)
300 <223> OTHER INFORMATION: Xaa at position 1 is PyroGlu
303 <220> FEATURE:
304 <221> NAME/KEY: MISC_FEATURE
305 <222> LOCATION: (6)..(6)
306 <223> OTHER INFORMATION: Xaa at position 6 is Ornithine
309 <220> FEATURE:
310 <221> NAME/KEY: MISC_FEATURE
311 <222> LOCATION: (10)..(10)
312 <223> OTHER INFORMATION: Xaa at position 10 is Gly-NH2
315 <400> SEQUENCE: 11
W--> 317 Xaa His Trp Ser Tyr Xaa Leu Arg Pro Xaa
318 1 5 10
321 <210> SEQ ID NO: 12
322 <211> LENGTH: 10
323 <212> TYPE: PRT
324 <213> ORGANISM: Artificial Sequence
326 <220> FEATURE:
327 <223> OTHER INFORMATION: Gonadotrophin Release Hormone Analogue
329 <220> FEATURE:
330 <221> NAME/KEY: MISC_FEATURE
331 <222> LOCATION: (1)..(1)
332 <223> OTHER INFORMATION: Xaa at position 1 is PyroGlu
335 <220> FEATURE:
336 <221> NAME/KEY: MISC_FEATURE
337 <222> LOCATION: (6)..(6)
338 <223> OTHER INFORMATION: Xaa at position 6 is Ornithine
341 <220> FEATURE:
342 <221> NAME/KEY: MISC_FEATURE
343 <222> LOCATION: (10)..(10)
344 <223> OTHER INFORMATION: Xaa at position 10 is ethylamide
347 <400> SEQUENCE: 12
W--> 349 Xaa His Trp Ser Tyr Xaa Leu Arg Pro Xaa
350 1 5 10
353 <210> SEQ ID NO: 13
354 <211> LENGTH: 10
355 <212> TYPE: PRT
356 <213> ORGANISM: Artificial Sequence
358 <220> FEATURE:
359 <223> OTHER INFORMATION: Gonadotrophin Release Hormone Analogue
361 <220> FEATURE:
362 <221> NAME/KEY: MISC_FEATURE
363 <222> LOCATION: (1)..(1)
364 <223> OTHER INFORMATION: Xaa at position 1 is PyroGlu
367 <220> FEATURE:

Please
correct this
error in
subsequent
sequences.

OK

15, 18, 21, 24, 27, 30,
33, 36, 46

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/810,601ADATE: 01/15/2003
TIME: 18:15:09Input Set : A:\D2947CIP 021211.ST25.txt
Output Set: N:\CRF4\01152003\I810601A.rawPlease Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 1
Seq#:2; Xaa Pos. 1,10
Seq#:3; Xaa Pos. 1,10
Seq#:4; Xaa Pos. 1,10
Seq#:5; Xaa Pos. 1,10
Seq#:6; Xaa Pos. 1,10
Seq#:7; Xaa Pos. 1,10
Seq#:8; Xaa Pos. 1,6,10
Seq#:9; Xaa Pos. 1,6,10
Seq#:10; Xaa Pos. 1,6,10
Seq#:11; Xaa Pos. 1,6,10
Seq#:12; Xaa Pos. 1,6,10
Seq#:13; Xaa Pos. 1,6,10
Seq#:14; Xaa Pos. 1,6,10
Seq#:15; Xaa Pos. 1,6,10
Seq#:16; Xaa Pos. 1,6,10
Seq#:17; Xaa Pos. 1,10
Seq#:18; Xaa Pos. 1,10
Seq#:19; Xaa Pos. 1,10
Seq#:20; Xaa Pos. 1,6,10
Seq#:21; Xaa Pos. 1,6,10
Seq#:22; Xaa Pos. 1,6,10
Seq#:23; Xaa Pos. 1,10
Seq#:24; Xaa Pos. 1,10
Seq#:25; Xaa Pos. 1,10
Seq#:26; Xaa Pos. 1,6,10
Seq#:27; Xaa Pos. 1,6,10
Seq#:28; Xaa Pos. 1,6,10
Seq#:29; Xaa Pos. 1,10
Seq#:30; Xaa Pos. 1,10
Seq#:31; Xaa Pos. 1,10
Seq#:32; Xaa Pos. 1,6,10
Seq#:33; Xaa Pos. 1,6,10
Seq#:34; Xaa Pos. 1,6,10
Seq#:35; Xaa Pos. 1,10
Seq#:36; Xaa Pos. 1,10
Seq#:37; Xaa Pos. 1,10
Seq#:38; Xaa Pos. 1,6,10
Seq#:39; Xaa Pos. 1,6,10
Seq#:40; Xaa Pos. 1,6,10
Seq#:46; Xaa Pos. 1,6,10
Seq#:51; Xaa Pos. 2,3,5

VERIFICATION SUMMARY

DATE: 01/15/2003

PATENT APPLICATION: US/09/810,601A

TIME: 18:15:09

Input Set : A:\D2947CIP 021211.ST25.txt

Output Set: N:\CRF4\01152003\I810601A.raw

L:33 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0
L:59 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:0
L:85 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3 after pos.:0
L:111 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4 after pos.:0
L:137 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 after pos.:0
L:163 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:0
L:189 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7 after pos.:0
L:221 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8 after pos.:0
L:253 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9 after pos.:0
L:285 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10 after pos.:0
L:317 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11 after pos.:0
L:349 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12 after pos.:0
L:381 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13 after pos.:0
L:413 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14 after pos.:0
L:445 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:15 after pos.:0
L:477 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16 after pos.:0
L:503 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:17 after pos.:0
L:529 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:18 after pos.:0
L:555 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19 after pos.:0
L:587 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20 after pos.:0
L:619 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:21 after pos.:0
L:651 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:22 after pos.:0
L:677 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23 after pos.:0
L:703 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:24 after pos.:0
L:729 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:25 after pos.:0
L:761 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:26 after pos.:0
L:793 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:27 after pos.:0
L:825 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:28 after pos.:0
L:851 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:29 after pos.:0
L:877 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:30 after pos.:0
L:903 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31 after pos.:0
L:935 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32 after pos.:0
L:967 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33 after pos.:0
L:999 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:34 after pos.:0
L:1025 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:35 after pos.:0
L:1051 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:36 after pos.:0
L:1077 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:37 after pos.:0
L:1109 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:38 after pos.:0
L:1141 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:39 after pos.:0
L:1173 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:40 after pos.:0
L:1274 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:46 after pos.:0
L:1368 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:51 after pos.:0